The FDA has approved durvalumab (Imfinzi) plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for the treatment ...

The PACIFIC-2 trial reveals that durvalumab with chemoradiotherapy offers no survival benefits for stage 3 NSCLC and ...

A phase 2 study reveals high efficacy and manageable safety of venetoclax plus obinutuzumab for untreated CLL/SLL in Japanese ...

AVZO-103 has received fast track designation for treating urothelial cancer patients previously treated with enfortumab ...

Benjamin George, MD, has significantly improved cancer care access in rural Nebraska, Colorado, and Kansas, transforming ...

Selinexor-based regimens enhance T-cell activation in RRMM patients, without increasing inhibitory checkpoint molecules, indicating resistance is not due to T-cell exhaustion. Baseline protein ...

Recent polling shows oncologists changing inclination in treatment for mHSPC based on tolerability profiles.

The median BMI of the cohort was 26.7 kg/m 2 (range, 17.9–55.2). Patients were classified into 3 main weight categories based ...

Findings from a recent clinical study (NCT05304793) show that cognitive behavioral therapy (CBT) can help patients with lung ...

RP1 and nivolumab combination achieved a 32.9% objective response rate and 15.0% complete response rate in advanced melanoma ...

During a live event, Praneeth Baratam, MBBS, discussed the molecular factors that affect staging of lower-risk myelodysplastic syndromes.

Topline results from the phase 3 HERIZON-GEA-01 trial show that the HER2-targeted bispecific antibody zanidatamab-hrii ...